

Bone health in epilepsy

HANNAH R. COCK

Epilepsy Group, Atkinson Morley Regional Neuroscience Centre, St Georges NHS Trust and Division of Clinical Sciences, University of London, Cranmer Terrace, London

The first case reports addressing bone health in epilepsy, specifically an association between antiepileptic drug (AED) use and abnormalities in bone metabolism, were some 40 years ago^{1,2} and prevalence rates of 50% or more have been reported for clinical and sub-clinical bone disorders in patients chronically treated with antiepileptic medication (comprehensively reviewed in Petty et al³). Interest has since escalated, particularly over the last decade, but despite this, a US-based survey in 2001⁴ suggests that this was an area largely neglected by treating neurologists in both adult and paediatric practice. Following this, editorials and reviews have been published on a regular basis, all highlighting what was hitherto a lack of familiarity with the current literature and urgent need for evidence-based guidelines. There seems now to be little doubt that epilepsy patients are at increased risk of fractures and metabolic bone disease, to an extent that we should be at least discussing with our patients. Recent studies also support that at least some of this risk is AED associated, and thus potentially preventable. However, many issues remain unresolved, including which of multiple mechanisms are most important, whether newer drugs offer advantages over older in this context, how best we should identify those most at risk, and what preventive treatment should be offered. National guidance in the UK does now recommend vitamin D supplementation. This chapter will review the currently available literature, and discuss recommendations based on this.

Definitions and assessment

The primary symptom of metabolic bone disease is an increased incidence of fracture. Both low bone mineral density (BMD) or bone mass⁵ and vitamin D deficiency⁶ are established independent risk factors for fracture.

Bone mineral density

Low BMD without fracture is usually referred to as osteopenia, whereas osteoporosis is traditionally defined as the occurrence of non-traumatic fractures, commonly of the spine, hip and wrists, in the setting of a low BMD⁷. In the healthy population BMD increases throughout childhood and adolescence, peaks at around 20 years of age, remains stable until age 40, and then steadily declines. There is considerable individual variability, of which 80% is due to hereditary factors including sex and ethnicity (Caucasian women have the highest incidence of osteopenia, with Afro-Americans relatively protected)⁸. Low levels of physical activity, smoking, alcohol and hormonal status (postmenopausal women, testosterone deficient men) are also known to be associated with reduced BMD.

The agreed gold standard for assessing BMD is dual energy X-ray absorptiometry (DEXA), which has an accuracy of 1–2% at any given site^{9,10}. Values can be obtained for whole bones or joints, or bone cortex or trabecular bone alone. Values taken from sites of potential fracture, ideally the total hip score, are considered the most valid. The spine is not suitable for diagnostic purposes, but can be used to follow treatment effects. Results are

usually expressed as T scores, representing the number of standard deviations (SD) from the mean peak BMD (at age 20) for that population (sex and ethnicity).

The relationship between BMD and risk of fracture is continuous, with an approximately two-fold increase in risk with each SD decrease in BMD¹¹. The World Health Organization has defined thresholds for BMD: a T score of >-1 is regarded as normal, values between -1 and -2.5 as osteopenic, and below -2.5 as osteoporotic⁷. Osteoporosis is considered severe/established if non-traumatic fractures occur in this setting. Z scores are also sometimes quoted, particularly for children, representing the number of SDs from age-matched population controls.

Whilst relationship between BMD and fracture risk is clearly established, the use of BMD alone to assess risk is not recommended. Although it has high specificity, the sensitivity is low (approximately 50%)¹², meaning that half of fractures will occur in patients said not to have osteoporosis on this measure.

Vitamin D metabolism

The major biologically active metabolite of vitamin D is 1,25 dihydroxy vitamin D, which, in addition to its roles in bone metabolism, has antiproliferative, prodifferentiation and immunosuppressive effects. Severe vitamin D deficiency results in defective mineralisation (osteomalacia, or rickets in the developing skeleton). Serum levels of 25-hydroxy vitamin D are usually measured, and the lower limit of normal is commonly set at <20 nmol/L. It is recognised that more subtle insufficiency, with levels up to 37.5 nmol/L, may be associated with secondary hyperparathyroidism and increased bone turnover, and play a role in age-related bone loss and osteoporosis¹³.

Dietary sources of vitamin D are limited, and in normal circumstances most is cutaneously synthesised, which is sunlight dependent. Thus populations who are housebound/institutionalised, or those who avoid sunlight for cultural reasons will by default rely more on dietary sources, and be at risk of deficiency. Intestinal, liver, renal or cardiopulmonary diseases are also risk factors due to secondary effects. Although frank osteomalacia/rickets is relatively rare in western societies, vitamin D insufficiency may be very common, affecting 57% of medical inpatients in one US study¹⁴. Importantly, many of these did not have known risk factors and thus would have been missed without screening.

Biochemical markers of bone turnover

In addition to assessing vitamin D levels, and traditional biochemical bone markers such as calcium, phosphate, parathyroid hormone and various other markers of bone turnover can easily be detected in blood and urine with commercially available kits. The bone isoform of serum alkaline phosphatase is the most commonly measured, but is relatively insensitive as a screening test. There are several serum markers of bone formation including osteocalcin (a non-collagenous matrix protein secreted by osteoblasts), and circulating peptides of Type I collagen. Similarly serum levels of peptides representing degraded products from osteoclastic activity (e.g. N-telopeptide of type I collagen) can be used to assess bone resorption¹⁵. Skeletal growth factors (e.g. insulin growth factor 1, IGF1) also play a role.

Bone turnover is increased during growth periods and fracture repair, and such markers have been correlated with histology from bone biopsy in both health and disease¹⁶. Such markers are increasingly cited in papers as indicators of metabolic bone disease¹⁷, but they have not been validated against clinically meaningful endpoints in prospective studies, and further research is required before they can be used to detect at risk individuals or monitor treatment.

Additional risks to patients with epilepsy

There are many reasons why patients with epilepsy might be at increased risk of bone disease, including reduced exposure to sunlight (housebound/institutionalised), frequent falls, and lower physical activity levels in patients with active epilepsy.

Fractures

Many of the early studies showing an increased incidence of fractures in patients with epilepsy were carried out in institutionalised patients^{18,19}, in whom low activity levels and poor sunlight exposure are important confounders. However, studies in the community and in ambulatory patients have confirmed a 2–3-fold increase in fractures in patients with epilepsy²⁰⁻²³. The most recent of these, from the UK GP database though retrospective, was population based, and included over 40,000 epilepsy patients and 80,000 controls²³, and found the overall incidence of fractures to be doubled in epilepsy patients compared to age and sex matched controls.

This was also the conclusion from a recent meta-analysis²⁴, with the highest relative risks for hip (x5.3) and spine (x6.2) fractures, as might be predicted if metabolic bone disease is contributory. Others have reported that up to one-third of the increased risk^{21,25} appears to be a direct result of injury during seizures, again something supported by the meta-analysis²⁴. Thus optimum seizure control, especially where there are convulsive seizures and/or falls, remains a primary goal when considering bone health. Avoiding the motor complications of AED treatment that might further predispose to falls is also important in this context, though has been little studied to date²⁶.

However the main concern is whether AEDs in themselves confer additional risks. Clearly this is important to establish, both in order to advise patients with mild/infrequent seizures and those in remission on the risks/benefits of continued AED treatment, and in terms of prevention/detection for patients continuing on AEDs. Some epidemiological studies in ambulatory patients^{21,25} found the increased risk of fractures in patients on AEDs was barely significant, once seizure-related fractures were excluded. Similarly in a recent population based case-control study, the relative increase in fracture for patients on enzyme inducing AEDs was modest (OR 1.38, 95% CI 1.31–1.45) after adjustment for cofounders (steroids, comorbidity, social variables, prior fracture), using any fracture as outcome, and used of AEDs as exposure variable²⁷. For non enzyme-inducers the risk was still statistically increased (OR 1.19, 95% CI 1.11–1.27), though less markedly. However, this was a huge study, totalling nearly 125,000 fractures, and a dose response relationship could be shown for carbamazepine, phenobarbitone, oxcarbazepine and valproate supporting that this is a biological drug effect, though not huge. Amongst individual drugs, a significant risk was not shown for any of the other newer drugs, but the authors acknowledge the study had insufficient power in this context.

That phenytoin and primidone also gave non-significant results almost certainly also reflects the small numbers on these drugs, and contrasts with the bulk of the literature. A large case-control study based on the UK GP database cited previously, which took account of many other confounders (though not diet and exercise), went a step further, also attempting to control for disease severity (using number of drugs/medical contacts as surrogate markers) and has shown a clear cumulative association with duration of AED use, each year of exposure being associated with a 9% increase in fracture risk²⁸. Thus it does appear that at least the older AEDs, including all enzyme inducers and valproate, are themselves associated with a modest increase in risk of fractures, and evidence is accumulating to support cause and effect. There is insufficient data to draw conclusions with respect to any of the newer AEDs.

Biochemical markers

Until very recently, nearly all published data had been in the form of case reports, cross-sectional, or retrospective studies, and thus subject to potential biases. Nonetheless there were some consistent findings.

Enzyme inducers, such as carbamazepine (CBZ), phenytoin (PHT) and phenobarbitone (PB), would be expected to increase hepatic vitamin D catabolism, increasing the risk of osteomalacia. This may be exacerbated by additional effects on sex hormones². Phenytoin is thought also to impair directly gastrointestinal calcium absorption²⁹. There are now many studies (only the most recent of which are cited here as examples) including in ambulatory children and adults, consistently demonstrating significantly increased bone alkaline phosphatase³⁰⁻³² (particularly with phenytoin), reduced 25-hydroxy vitamin D3 levels^{30,33,34}, reduced serum calcium^{30,32}, and mildly elevated serum PTH³⁴ in patients on enzyme-inducing AEDs compared with matched controls. Conflicting data has been reported with oxcarbazepine^{31,35}, and although most of the published data pre-dates topiramate (TOP) similar effects might be expected.

Other markers of bone turnover also appear to be consistently elevated in patients on AEDs, both enzyme-inducing^{15,36,37} and non-inducing, such as valproate (VPA)^{38,39}. However, not all studies are consistent in terms of specific markers or individual drugs, and in terms of detail there are many conflicting results.

A number of prospective studies have also now been reported. Markers of bone turnover were assessed before treatment was started in 60 children with epilepsy and two years later¹⁵, and showed significant increases in patients on CBZ compared to a well matched control group. All patients were seizure free within a month, so the differences cannot be attributed to seizures, and were independent of pubertal stage. Similarly a prospective monitoring study comparing 51 ambulatory children with 80 controls over up to three years showed a significant decreasing trend in vitamin D, and an increase in serum PTH in children on carbamazepine or valproate. Nearly half the children acquired hypovitaminosis D during the study. Of note, this study also looked at seasonal variation (presumed to be related to sun exposure), which was present but did not account for the group differences⁴⁰. Similar changes have also been prospectively reported in adults on VPA⁴¹. Many of these studies have also evaluated vitamin D status, and demonstrated that increased bone turnover appears to be independent of the presence of hypovitaminosis D. It is thought some AEDs, including CBZ and VPA may have direct effects on osteoclast/osteoblast activity⁴².

Taken together, AEDs, particularly though not exclusively enzyme inducers, do appear to have effects on biochemical markers of bone metabolism, offering a number of biologically plausible mechanisms that might underlie increased fracture risk. Hypovitaminosis D is considered an independent risk factor for fracture, and may have other consequences including muscle weakness and increased liability to falls⁴³, thus should reasonably be considered a 'warning' of clinically significant metabolic bone disease. It is also worryingly prevalent (40–80%) in epilepsy populations, both in the developed⁴⁴ and the developing world⁴⁵, and may develop very quickly (within months) of starting AEDs. However, other markers of increased bone turnover in themselves are not consistently associated with reduced BMD either in adults^{36,41} or children³⁸. 'AED bone disease' should probably not be considered synonymous with osteoporosis, which is supported by histomorphometric data, albeit limited, illustrating increased bone remodelling⁴⁶, and not necessarily decreased cortical bone mass. Thus, whilst illustrating that there are changes to

bone metabolism, the clinical significance of many of the biochemical findings, with the exception of hypovitaminosis D, is currently uncertain, and requires further study.

BMD

Given the limitations of biochemical markers, BMD remains the gold standard in terms of assessing fracture risk, monitoring disease and treatment effects in metabolic bone disease, and several studies, mostly cross-sectional or retrospective have now reported on BMD in epilepsy patients. Many of the studies claiming a significant reduction in BMD with both enzyme-inducing AEDs^{47,48} and VPA^{39,49} use non-validated methods/sites and are thus difficult to interpret. However those that use DEXA scanning at appropriate sites (spine, hip), and take adequate care to control for confounders mostly support that AED use is independently associated with reduced BMD, at least in adults on older AEDs. One study found a significant association only for PHT³⁶, but most show reduced BMD in adults on any of the older AEDs (PHT, PB, CBZ, VPA)^{33,34,50} in whom up to 59% are classified as osteopenic, and 23% as osteoporotic by WHO definitions. However the studies are inconsistent as to the size of any AED effect, and whether or not this reduction correlates with either duration of AED therapy, or specific drug classes.

Studies in children are less consistent, and generally smaller, with an inevitably bigger spread of data reflecting various growth stages. Several well controlled earlier studies have not found any significant reduction in DEXA Z scores in children taking CBZ^{38,51-54}. Others have found BMD reductions associated with treatment, though often without adequate controls for potential confounders^{55,56}. The most recent of these also suggest more loss with longer durations of treatment, and that if anything young males may be most affected⁵⁷. Similarly there are conflicting reports for VPA^{30,38,51-55,58}. Whether the more inconsistent nature of reports in children reflects purely methodological difficulties, shorter duration of AED therapy, that there is simply more spare capacity in younger bones that will be unmasked in later life, or that young skeletons are better able to tolerate metabolic challenges remains unclear.

As for biochemical markers, prospective longitudinal studies offer the greatest potential, but as yet few have been undertaken, and where they have been the numbers are relatively small, and confounders not always adequately controlled for. Of 30 children on carbamazepine, valproate or phenobarbitone studied at the beginning of AED monotherapy and after two years of treatment, two developed 'drug-induced osteopenia' on DEXA scores (6.7%)⁵⁹. In the largest prospective series 81 epileptic men aged 25-54 on a mixture of new and old AEDs had DEXA scans 12-29 months (mean 19 months) apart. Thirteen patients who had commenced taking bone anti-resorptive therapy were excluded. Younger men (age 25-44) demonstrated a significant mean bone loss of 1.8% per year at the femoral neck, although the reason for the fact that these changes were seen only in the younger population is unclear from the data presented³⁴.

In another study, adult men and women (n = 50)⁴¹, all on valproate, were compared with controls and had repeat DEXAs six months apart. At the first visit, the valproate user group had significantly lower BMD values at both proximal femur and lumbar spine sites. Six months later there was a mean bone loss in the valproate users of 4.9% at the lumbar spine and 4.6% at the femur, with a significant inverse relationship between duration of valproate use and all DEXA values, although the comparable data for controls were not presented. Overall, despite methodological limitations and small numbers, the message is at least consistent in supporting that AEDs probably do cause bone problems though despite the fact that all these prospective studies also included biochemical parameters, the mechanisms remain uncertain, as correlation between biochemical changes and BMD was generally absent.

Attributable risk

In addition to epilepsy-based studies, prevalence data from various populations consistently report AED use as an independent risk factor for markers of bone disease: AED use is associated with increased fracture rates amongst ITU patients⁶⁰, hip fracture rates in Caucasian women in the community⁶¹, and hypovitaminosis D in medical inpatients¹⁴. Thus overall, even allowing for confounders, the consistency of the message across different studies using different methodologies suggests this is a real association. What is more difficult to ascertain is how significant this is in clinical terms. In one study (men only) to include sequential scans two years apart, bone loss of an estimated 1.8% per year was attributable to AED use, and this was a more important risk factor than either smoking or alcohol³⁴.

A prospective community-based study of osteoporotic fractures in over 9000 women over 65, has recently reported on AED use and BMD (hip and calcaneus DEXA) with an average of 5.7 years between scans⁶². With careful adjustment for confounders, the average rate of decline in total hip BMD increased from 0.7%/year in non-AED users (ever), to -0.87%/year in 'partial users' (AEDs at some time during the study, but not throughout), to -1.16%/year in continuous users (*P* for trend 0.015). Whilst these numbers sound small, such is the importance of BMD, this translates to a nearly 30% increase in the risk of hip fracture over five years, associated with AED use. Phenytoin looked the worst offender, but was also the most commonly used AED, and smaller changes with other AEDs in this study may have been masked by smaller numbers. As would be expected, the AED users were also different in other respects, e.g. as a group having less good general health, being thinner and more depressed. HRT and exercise also came through as protective factors, independent of AED usage. Across mixed-sex populations, sex and hormonal status almost certainly have a larger influence, and AED use has been estimated to contribute to only 5% of the total variation in BMD at the femoral neck⁵⁰. However, this does not mean men should be complacent: using the same methods as described above, Ensrud et al⁶³ have also reported a community-based prospective BMD study in 4000 men over 65. As expected, all rates of decline were lower, but men taking notable non-enzyme inducing AEDs at both visits, an average of 4.6 years apart, still did have significantly greater rates of loss (0.53%/year vs 0.35%/year in non-users. Thus as a potentially remedial iatrogenic cause the overall message should be cause for concern.

Case finding, treatment and prevention

On this background of confusing information, what then should we advise our patients, while awaiting the outcome of much needed further research? Much of the literature debate on this topic considers AED bone disease as a type of osteoporosis. As discussed above, this may not be strictly accurate, but given that BMD (as a measure of osteopenia/osteoporosis) is clearly related to fracture risk, and that we do have effective treatments to slow declining BMD, from a pragmatic/treatment point of view this is probably reasonable, at least until further information is available.

Published consensus guidelines¹² on the treatment and prevention of osteoporosis continue to argue, as they have done since the late 1990s, against primary prevention on the grounds that most osteoporotic fractures do not occur in the small groups at very high risk, but in the larger numbers at moderate risk. Thus population-wide interventions would be required for good effect. The problem then is that, although the population attributable risk is high, absolute individual risk for most is low, and the safety, feasibility and cost of any intervention are especially crucial and, as yet, largely not established. Instead it is

recommended that the major thrust of osteoporosis prevention should be directed towards selective case-finding.

DEXA case-finding/screening of at risk populations

In line with this, population screening with for example DEXA scans is also not recommended, but should be used only as a case-finding strategy for individuals already considered at risk¹². Biochemical markers are considered as having ‘the potential to aid risk assessment’ (and treatment monitoring), but their utility in clinical practice still in need of further evaluation. Thus despite recommendations from some that DEXA and biochemical markers of bone turnover should be routinely studied in patients on AEDs⁴⁶, the evidence to support anything beyond the standard bone profile every 2–5 years⁶⁴ (unchanged in the 2011 draft) is lacking. A huge amount of work has gone into the development of algorithms to identify individuals at risk, culminating in the web-based FRAX tool (<http://www.shef.ac.uk/FRAX>). This asks for basic demographics and additional clinical information on proven risks (low body mass index; prior characteristic fracture; parental hip fracture; alcohol intake; smoking; rheumatoid arthritis, glucocorticoid treatment; other known cause secondary osteoporosis), leading to a 10-year probability of hip or major osteoporotic fracture estimate for any individual over 40 to guide future management. This has been externally validated in independent cohorts, and guides the clinician as to whether DEXA is indicated (or in some instances not required, if BMD is already known or the clinical picture already points to the need for treatment). That this can only be applied to individuals over 40, and is recommended only for postmenopausal women and men over 50 years, reflects that the biggest risk factor for fracture, independent of BMD, is age. Accepted secondary causes include type I (insulin dependent) diabetes, osteogenesis imperfecta in adults, untreated long-standing hyperthyroidism, hypogonadism or premature menopause (<45 years), chronic malnutrition, or malabsorption and chronic liver disease management and, probably most significant in our patient population, prolonged immobility. It is tempting, as some have⁶⁵, having considered the accumulating evidence of risk in patients with epilepsy, to think that epilepsy or AED treatment *per se* should also be considered a recognised secondary cause in this model, and to recommend BMD screening in patients with ‘prolonged’ exposure or any additional risk factors. However, the evidence to do so is certainly not as persuasive as it is for some other conditions. For example the odds ratio for fracture risk in patients on long-term glucocorticoid treatment⁶⁶ ranges from around 2 (hip) to over 5 (spine) after as little as six months’ treatment, compared to the ~1.4 OR that might be attributable to AEDs (excluding seizure-related fractures) after many years. Importantly, the cost, clinical effectiveness and service implications of including epilepsy patients as a high-risk group have also barely been evaluated, though perhaps are deserving of further research to inform future practice. This presumably is the basis of epilepsy/AEDs not being included in what after all is an international, WHO-backed consensus guideline updated as recently as 2010¹².

Calcium and vitamin D supplements

The argument for ensuring adequate vitamin D levels in all patients on AEDs, notwithstanding that there are undoubtedly vitamin D independent mechanisms³³, is far stronger than for DEXA scanning. As previously discussed, hypovitaminosis D appears to be a widespread problem, not just in epilepsy patients, and is an independent risk factor for fracture. Vitamin D is cheap, well tolerated, and supplementation is of proven efficacy in community-based studies of high-risk groups (principally the elderly), both with calcium¹³ and alone⁶⁷, irrespective of vitamin D status. Two randomised controlled trials of vitamin D supplementation in ambulatory children and adults on AEDS have now been reported together⁶⁸. In adults, in whom the baseline BMD was lower than in control populations

consistent with other studies, after one year of supplementation only high-dose (4000 IU/day), and not low-dose (400 IU/day) vitamin D was effective as assessed by BMD increases. In children, baseline BMD was normal, but increased in both low- and high-dose treatment groups. Reflecting this, national guidance now exists recommending that vitamin D supplementation should be considered for at risk patients taking long-term enzyme-inducing AEDs or valproate⁶⁹. ‘At risk’ and ‘long-term’ are however not defined, there is no guidance on dose or what levels to aim for in this population, and the exclusion of those on newer non-enzyme-inducing AEDs may well reflect absence of evidence, rather than evidence of safety.

Although the standard recommended daily intake is 400 IU/day, and this is the most readily available form in combination with calcium, most published trials (not specific to epilepsy) use doses equal to 800–1100 IU/day, either daily or as a three-monthly bolus. There is also data supporting that patients on AEDs probably require higher doses, perhaps up to 4000 IU/day⁷⁰⁻⁷² or in some instances over 50 times the normal daily dose of vitamin D to overcome the enzyme inducing effects of phenytoin⁷³, and in the epilepsy trials cited above, it was only the high dose (4000 IU in adults) which was effective. There is also ongoing international debate about what the ‘normal’ ranges and recommended daily intakes should be, with a growing expert body pushing for an increase in the acceptable lower level and recommended intakes⁷⁴. There is additionally no consensus on when such supplementation might be most beneficial. While a pragmatic view might be only to provide supplements to older patients most at risk, some studies have suggested that the young adult skeleton, particularly in men, is most at risk of AED-induced bone loss^{34,57}, and from the one trial in epilepsy, even low doses might be enough in children⁶⁸. Even high doses of vitamin D alone (i.e. without similarly high doses of calcium) are generally considered safe, with the minimal risk of unmasking untreated hyperparathyroidism almost certainly outweighed by the benefits. Annual costs (BNF 2010) per patient vary from £25 (standard 400 IU and calcium supplement) to £250 or more for higher doses of some formulations of vitamin D alone, many of which are less readily available and licensed only for confirmed insufficiency. For comparison, a vitamin D serum level costs around £15 to the NHS (personal communication, St George’s NHS Trust 2011), and screening has been recommended by the authors of a recent and balanced comprehensive review³. Together with the suggestion that even low doses might be sufficient in children (perhaps because started earlier in their treatment history, though this has not been proven), and a recent study showing that standard supplementation from the outset can prevent otherwise rapid falls on starting AEDs⁷⁵ my own practice in this context has recently shifted towards standard supplementation (calcium and 400 IU vitamin D) early on for all, and screening in those on treatment for two years or more to identify those in need of higher doses for at least a short period. Though ideally this should be undertaken in the context of ongoing audit/research, this is currently precluded by resource limitations.

Treatment of identified cases

Other than ensuring adequate vitamin D, a broad range of treatment options are now available for osteoporosis including hormone replacement therapy (oestrogen in postmenopausal women, testosterone in men), bisphosphonates, recombinant PTH, oestrogen-receptor modulators, monoclonal antibodies with effects on bone turnover, and calcitonin. No trials have been powered to detect differences in the magnitude of fracture reduction between treatments, and the vast majority have been undertaken in postmenopausal women, with little evidence in younger age groups, and also less in men, though there is no evidence that skeletal metabolism differences are fundamental between the sexes. Low-cost generic bisphosphonates which have a broad spectrum of effects are usually first line in the absence of contraindications. While previous guidelines

recommended treatment of T scores below -2.5, current guidance requires that age, T score and the number of additional clinical risk factors (including presence of a fragility fracture) are taken into account, such that in a postmenopausal woman without additional risks, alendronate (the cheapest option) would not be recommended until she was at least 70 with a T score of at least -3.0. Whether and how often to perform repeat scans of patients with intermediate scores (-1 to -2.5) other than in patients on glucocorticoids (usually recommended every 1–3 years) remains controversial, and patient management should anyway be undertaken with local osteoporosis specialists.

Far greater emphasis is put on looking for secondary causes, especially in men, identifying and if possible addressing lifestyle factors on a population basis, as well as addressing risk factors (individual and environmental) for falls. In this context the possible contribution of AEDs to fall risk has only recently started to be addressed systematically⁷⁶, and perhaps deserves further study.

Conclusions

There is accumulating evidence that patients on AEDs are at increased risk of metabolic bone disease and fracture for several reasons. Most of the evidence relates to the older drugs, most of which are enzyme inducers but including valproate, and there is really insufficient evidence to draw any conclusions about the safety or not of newer AEDs in the context of bone health. Animal studies⁷⁷ suggest that multiple mechanisms are involved, many independent of enzyme inhibition, and that newer drugs may be equally culpable.

So what should we do? As a minimum, in line with population guidance, clinicians should be actively thinking about bone health for patients with epilepsy and offering advice to all on regular exercise, diet, smoking and alcohol, including intake of at least 1000 mg/day of dietary calcium, and at least 400 IU/day of vitamin D. A standard supplement for all patients starting AEDs is perhaps justifiable and probably cost-effective, with screening to identify those in need of higher vitamin D doses in keeping with the recommended 2–5 year ‘bone profile’.

There is insufficient evidence to justify regarding patients with epilepsy as any different from other groups with respect to DEXA scanning and treatment, and they should thus be managed in line with population guidance in this context. This means that for patients over 40 years, clinicians should be asking about additional risk factors which might ‘tip the balance’ such as prior fragility fractures, other secondary causes (of which prolonged immobility probably the most prevalent in the epilepsy population), and family history, noting those with other recognised secondary causes, and where appropriate utilising the FRAX tool to guide further investigation and management. In terms of who should be driving this in patients with epilepsy, national guidelines put the onus of responsibility very much in the hands of the GP to monitor the use of medications that might be associated with falls or fracture, to ensure prescription of calcium and vitamin D and to encourage adherence to therapy¹².

However, it is also known that patients with epilepsy are less well informed on bone health issues than the general population⁷⁸. Whether this reflects poor knowledge among those managing epilepsy, the higher prevalence of learning, memory and psychosocial problems in patients with epilepsy, or that for the general physician managing a patient with epilepsy bone health simply falls down the list of priorities is not known. However, pending additional evidence on screening, prevention and treatment in relation to bone health in epilepsy, dependent on much needed further research, at least for the time being, my own view is that this is an area neurologists need to lead on.

References

1. KRUSE R. Osteopathien bei antiepileptischer Langzeittherapie. *Monatsschr Kinderheilkd* 1968;116:378–81.
2. HAHN TJ, BIRGE SJ, SCHARP CR, AVIOLI AV. Phenobarbital-induced alterations in Vitamin D metabolism. *J Clin Invest* 1972;51:741–8.
3. PETTY SJ, O'BRIEN TJ, WARK JD. Anti-epileptic medication and bone health. *Osteoporosis Int* 2007;18:129–42.
4. VALMADRID C, VOORHEES C, LITT B, SCHNEYER CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. *Arch Neurol* 2001;58:1369–74.
5. FAULKNER KG. Bone matters: are density increases necessary to reduce fracture risk? *J Bone Min Res* 2000;15:183–7.
6. LEBOFF MS, KOHLMEIER L, HURWITZ S, FRANKLIN J, WRIGHT J, GLOWACKI J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. *JAMA* 1999;281:1505–11.
7. RIGGS BL, MELTON LJ. The worldwide problem of osteoporosis - insights afforded by epidemiology. *Bone* 1995;17:S505–S511.
8. SHETH RD, HOBBS GR, RIGGS JE, PENNEY S. Bone mineral density in geographically diverse adolescent populations. *Pediatrics* 1996;98:948–51.
9. CONRAD CJ. Clinical use of bone densitometry. *N Engl J Med* 1991;324:1105–9.
10. COMPSTON J. Prevention and treatment of osteoporosis – Clinical guidelines and new evidence. *J Royal Coll Physicians Lond* 2000;34:518–21.
11. Royal College of Physicians Consensus Group. Osteoporosis – clinical guidelines: summary and recommendations, 1–13, 1999. London, Royal College of Physicians.
12. COMPSTON J, COOPER A, FRANCIS R et al. Osteoporosis: clinical guideline for prevention and treatment, 1–24, 2010. Sheffield, National Osteoporosis Guideline Group.
13. COMPSTON JE. Vitamin D deficiency: time for action. *Br Med J* 1998;317:1466–7.
14. THOMAS MK, LLOYD-JONES DM, THADHANI RI et al. Hypovitaminosis D in medical inpatients. *N Engl J Med* 1998;338:777–83.
15. VERROTTI A, GRECO R, LATINI T, MORGESE T, CHIARELLI F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. *Epilepsia* 2002;43:1488–92.
16. ERIKSEN EF, CHARLES P, MELSEN F, MOSEKILDE L, RISTELI L, RISTELI J. Serum markers of type-I collagen formation and degradation in metabolic bone disease – correlation with bone histomorphometry. *J Bone Min Res* 1993;8:127–32.
17. NISHIZAWA Y, NAKAMURA T, OHATA H et al. Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). *J Bone Min Metab* 2001;19:338–44.
18. HARRINGTON MG, HODKINSON HM. Anticonvulsant drugs and bone disease in the elderly. *J Roy Soc Med* 1987;80:425–7.
19. NILSSON OS, LINDHOLM TS, ELMSTEDT E, LINDBACK A, LINDHOLM TC. Fracture incidence and bone-disease in epileptics receiving long term anticonvulsant drug treatment. *Arch Orthopaed Trauma Surg* 1986;105:146–9.
20. ANNEGERS JF, MELTON LJ, SUN CA, HAUSER WA. Risk of age related fractures in patients with unprovoked seizures. *Epilepsia* 1989;30:348–55.
21. NEUFELD MY, VISHNE T, CHISTIK V, KORCZYK AD. Life-long history of injuries related to seizures. *Epilepsy Res* 1999;34:123–7.
22. PERSSON HBI, ALBERTS KA, FARAHMAND BY, TOMSON T. Risk of extremity fractures in adult outpatients with epilepsy. *Epilepsia* 2002;43:768–72.
23. SOUVEREIN PC, WEBB DJ, PETRI H, WEIL J, VAN STAA TP, EGBERTS T. Incidence of Fractures among Epilepsy Patients: A Population-based Retrospective Cohort Study in the General Practice Research Database. *Epilepsia* 2005;46:304–10.
24. VESTERGAARD P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. *Acta Neurologica Scand* 2005;112:277–86.
25. VESTERGAARD P, TIGARAN S, REJNMARK L, TIGARAN C, DAM M, MOSEKILDE L. Fracture risk is increased in epilepsy. *Acta Neurologica Scand* 1999;99:269–75.
26. ZACCARA G, CINCOTTA M, BORGHERESI A, BALESTRIERI F. Adverse motor effects induced by antiepileptic drugs. *Epileptic Disorders* 2004;6:153–68.
27. VESTERGAARD P, REJNMARK L, MOSEKILDE L. Fracture risk associated with use of antiepileptic drugs. *Epilepsia* 2004;45:1330–7.
28. SOUVEREIN PC, WEBB DJ, WEIL JG, VAN STAA P, EGBERTS ACG. Use of antiepileptic drugs and risk of fractures - Case-control study among patients with epilepsy. *Neurology* 2006;66:1318–24.
29. CROSLY CJ, CHEE C, BERMAN PH. Rickets associated with long-term anticonvulsant therapy in a pediatric outpatient population. *Pediatrics* 1975;56:52–7.
30. KUMANDAS S, KOKLU E, GUMUS H et al. Effect of carbamazepine and valproic acid on bone mineral density, IGF-I and IGFBP-3. *J Pediatr Endocrinol Metab* 2006;19:529–34.
31. MINTZER S, BOPANA P, TOGURI J, DESANTIS A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. *Epilepsia* 2006;47:510–5.
32. PACK AM, MORRELL MJ, MARCUS R et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. *Ann Neurol* 2005;57:252–7.

33. FARHAT G, YAMOUT B, MIKATI MA, DEMIRJIAN S, SAWAYA R, FULEIHAN GEH. Effect of antiepileptic drugs on bone density in ambulatory patients. *Neurology* 2002;58:1348–53.
34. ANDRESS DL, OZUNA J, TIRSCHWELL D et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. *Arch Neurol* 2002;59:781–6.
35. CETINKAYA Y, KURTULMUS YS, TUTKAVUL K, TIRELI H. The effect of oxcarbazepine on bone metabolism. *Acta Neurologica Scand* 2009;120:170–5.
36. VALIMAKI MJ, TIIHONEN M, LAITINEN K et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone-formation and resorption in patients on antiepileptic drugs. *J Bone Min Res* 1994;9:631–7.
37. VERROTTI A, GRECO R, MORGESE G, CHIARELLI F. Increased bone turnover in epileptic patients treated with carbamazepine. *Ann Neurol* 2000;47:385–8.
38. ALTAY EE, SERDAROGLU A, TUMER L, GUCUYENER K, HASANOGLU A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. *J Pediatr Endocrinol Metabol* 2000;13:933–9.
39. SATO Y, KONDO I, ISHIDA S et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. *Neurology* 2001;57:445–9.
40. NICOLAIDOU P, GEORGOULI H, KOTSALIS H et al. Effects of anticonvulsant therapy on vitamin D status in children: Prospective monitoring study. *J Child Neurol* 2006;21:205–9.
41. BOLUK A, GUZELIPEK M, SAVLI H, TEMEL I, OZISIK HI, KAYGUSUZ A. The effect of valproate on bone mineral density in adult epileptic patients. *Pharmacological Research* 2004;50:93–7.
42. PACK AM, MORRELL MJ. Adverse effects of antiepileptic drugs on bone structure – Epidemiology, mechanisms and therapeutic implications. *CNS Drugs* 2001;15:633–42.
43. HELLER HJ, SAKHAE K. Anticonvulsant-induced bone disease - A plea for monitoring and treatment. *Arch Neurol* 2001;58:1352–3.
44. SHELLHAAS RA, BARKS AK, JOSHI SM. Prevalence and Risk Factors for Vitamin D Insufficiency Among Children With Epilepsy. *Pediatr Neurol* 2010;42:422–6.
45. MENON B, HARINARAYAN CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism--a longitudinal study. *Seizure* 2010;19:153–8.
46. DREZNER MK. Treatment of anticonvulsant drug-induced bone disease. *Epilepsy Behav* 2004;5 Suppl 2:S41–S47.
47. KUBOTA F, KIFUNE A, SHIBATA N et al. Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study. *Epilepsy Res* 1999;33:93–7.
48. PEDRERA JD, CANAL ML, CARVAJAL J et al. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. *Eur J Clin Invest* 2000;30:895–9.
49. RIEGER-WETTENGL G, TUTLEWSKI BR, STABREY A et al. Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. *Pediatrics* 2001;108:art-e107.
50. STEPHEN LJ, MCLELLAN AR, HARRISON JH et al. Bone density and antiepileptic drugs: a case-controlled study. *Seizure* 1999;8:339-42.
51. SHETH RD, WESOLOWSKI CA, JACOB JC et al. Effect of carbamazepine and valproate on bone-mineral density. *J Pediatr* 1995;127:256–62.
52. AKIN R, OKUTAN V, SARICI U, ALTUNBAS A, GOKCAY E. Evaluation of bone mineral density in children receiving antiepileptic drugs. *Pediatr Neurol* 1998;19:129–31.
53. KAFALI G, ERSELCAN T, TANZER F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. *Clinical Pediatrics* 1999;38:93–8.
54. ECEVIT CG, AYDOGAN A, KAVAKLI T, ALTINOZ S. Effect of carbamazepine and valproate on bone mineral density. *Pediatr Neurol* 2004;31:279–82.
55. BABAYIGIT A, DIRIK E, BOBER E, CAKMAKCI H. Adverse effects of antiepileptic drugs on bone mineral density. *Pediatr Neurol* 2006;35:177–81.
56. SHETH RD, BINKLEY N, HERMANN BP. Progressive bone deficit in epilepsy. *Neurology* 2008;70:170–6.
57. SHETH RD, BINKLEY N, HERMANN BP. Gender differences in bone mineral density in epilepsy. *Epilepsia* 2008;49:125–31.
58. TSUKAHARA H, KIMURA K, TODOROKI Y et al. Bone mineral status in ambulatory pediatric patients on long- term anti-epileptic drug therapy. *Pediatrics International* 2002;44:247–53.
59. TEKGUL H, SERDAROGLU G, HUSEYINOV A, GOKBEN S. Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy. *J Child Neurol* 2006;21:411–4.
60. DESAI TK, CARLSON RW, GEHEB MA. Prevalence and clinical implications of hypocalcaemia in acutely ill patients in a medical intensive care setting. *Am J Med* 1988;84:209–14.
61. CUMMINGS SR, NEVITT MC, BROWNER WS et al. Risk factors for hip fracture in white women. *N Engl J Med* 1995;332:767–73.
62. ENSRUD KE, WALCZAK TS, BLACKWELL T, ENSRUD ER, BOWMAN PJ, STONE KL. Antiepileptic drug use increases rates of bone loss in older women - A prospective study. *Neurology* 2004;62:2051–7.
63. ENSRUD KE, WALCZAK TS, BLACKWELL TL, ENSRUD ER, BARRETT-CONNOR E, ORWOLL ES. Antiepileptic drug use and rates of hip bone loss in older men – A prospective study. *Neurology* 2008;71:723–30.

64. NICE. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 20, 1–73, 2004. London, National Institute for Clinical Excellence.
65. PACK A. Bone health in people with epilepsy: Is it impaired and what are the risk factors. *Seizure* 2008;17:181–6.
66. Royal College of Physicians Consensus Group. Glucocorticoid-induced osteoporosis: a concise guide to prevention and treatment, 2003. London, Royal College of Physicians.
67. TRIVEDI DP, DOLL RD, KHAW KT. Effect of four monthly oral Vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *Br Med J* 2003;326:469–72.
68. MIKATI MA, DIB L, YAMOUT B, SAWAYA R, RAHI AC, FULEIHAN GEH. Two randomized vitamin D trials in ambulatory patients on anticonvulsants – Impact on bone. *Neurology* 2006;67:2005–14.
69. MHRA. Antiepileptics: adverse effects on bone. *Drug Safety Update* 2009;2:2.
70. COLLINS N, MAHER J, COLE M, BAKER M, CALLAGHAN N. A prospective study to evaluate the dose of vitamin-D required to correct low 25-hydroxyvitamin D levels, calcium and alkaline phosphatase in patients at risk of developing antiepileptic drug induced osteomalacia. *Q J Med* 1991;78:113–22.
71. NASHEF L, LAMB E. Vitamin D deficiency – Guidelines are needed for treating diseases of bone metabolism in epilepsy. *Br Med J* 1999;318:1285.
72. COMPSTON JE. Vitamin D deficiency – Guidelines are needed for treating diseases of bone metabolism in epilepsy – Reply. *Br Med J* 1999;318:1285.
73. SHETH RD. Bone health in epilepsy. *Lancet Neurology* 2004;3:516.
74. VIETH R, BISCHOFF-FERRARI H, BOUCHER BJ et al. The urgent need to recommend an intake of vitamin D that is effective. *Am J Clin Nutr* 2007;85:649–50.
75. KRISHNAMOORTHY G, NAIR R, SUNDAR U, KINI P, SHRIVASTAVA M. Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: a prospective study. *Neurol India* 2010;58:213–9.
76. POMEROY VM, HISCOCK A, COCK HR, TALLIS RC. Impact of carbamazepine on postural control in older adults: an exploratory study. *Physiotherapy* 2008;94:230–5.
77. NISSEN-MEYER LS, SVALHEIM S, TAUBOLL E, GJERSTAD L, REINHOLT FP, JEMTLAND R. How can antiepileptic drugs affect bone mass, structure and metabolism Lessons from animal studies. *Seizure* 2008;17:187–91.
78. ELLIOTT JO, JACOBSON MP. Bone loss in epilepsy: Barriers to prevention, diagnosis, and treatment. *Epilepsy Behav* 2006;8:169–75.